resistance mechanism of human immunodeficiency virus type-1 protease to inhibitors: a molecular dynamic approach

human immunodeficiency virus type 1 (hiv-1) protease inhibitors comprise an important class of drugs used in hiv treatments. however, mutations of protease genes accelerated by low fidelity of reverse transcriptase yield drug resistant mutants of reduced affinities for the inhibitors. this problem is considered to be a serious barrier against hiv treatment for the foreseeable future. in this study, molecular dynamic simulation method was used to examine the combinational and additive effects of all known mutations involved in drug resistance against fda approved inhibitors. results showed that drug resistant mutations are not randomly distributed along the protease sequence; instead, they are localized on flexible or hot points of the protein chain.  substitution of more hydrophobic residues in flexible points of protease chains tends to increase the folding, lower the flexibility and decrease the active site area of the protease. the reduced affinities of hiv-1 protease for inhibitors seemed to be due to substantial decrease in the size of the active site and flap mobility. a correlation was found between the binding energy of inhibitors and their affinities for each mutant suggesting the distortion of the active site geometry in drug resistance by preventing effective fitting of inhibitors into the enzymes' active site. to overcome the problem of drug resistance of hiv-1 protease, designing inhibitors of variable functional groups and configurations is proposed.